Name of Journal: World Journal of Clinical Cases
Manuscript NO: 75345
Manuscript Type: CASE REPORT

Loss of HER2 in HER2+ breast cancer after neoadjuvant treatment: A case report

Jing Yu, Nan-Lin Li
Abstract

BACKGROUND

HER2 expression has been reported to be discordant between primary tumor and metastatic tissue.

CASE SUMMARY

We presented a case diagnosed with the HER2+ breast cancer patient who exhibited changes in the expression of HER2 receptors on tumour samples from surgical specimens obtained after neoadjuvant treatment (NAT) compared with initial biopsy. The patient underwent a HER2-targeted therapy consequently, in spite of HER+ gene loss. After the surgery, the patient subsequently underwent endocrine therapy and radiotherapy.

CONCLUSION

Changes in HER2 expression after NAT should be retested by physicians and pathologists before systemic treatment instead of avoiding further HER2-targeted therapy, and we will perform IHC multiple-spot biopsy analyses of other important clinical issues to better define prognosis and tailor subsequent adjuvant therapy.

Key Words: HER2+ breast cancer; HER2 Loss; Neoadjuvant treatment; Case report

Yu J, Li N. Loss of HER2 in HER2+ breast cancer after neoadjuvant treatment: Case report and literature review. World J Clin Cases 2022; In press

Core Tip: Neoadjuvant treatment (NAT); Immunohistochemical (IHC); Fluorescence In Situ Hybridization (FISH)

INTRODUCTION
The HER2 gene is over-expressed in approximately 15%-20% of primary breast cancers, and HER2-targeted therapies are associated with significantly improved survival. Neoadjuvant treatment (NAT) is the standard of care for HER2-positive early breast cancer, especially for positive pathologic axillary lymph nodes. However, HER2 expression has been reported to be discordant between the primary tumour and the remaining tumour after NAT and is associated with poor prognosis and treatment. Data regarding HER2 Loss suggest that 2.3%-43% of post-treatment tumours lose HER2 positivity, which is associated with worse survival[1-3]. Herein, by reviewing the relevant literature, we present a case of HER2 Loss with HER2+ breast cancer undergoing NAT, to determine the prognostic impact of HER2 Loss and improve disease management.

**CASE PRESENTATION**

*Chief complaints*

She complained of a mass in her left breast for several months.

*History of present illness*

A 55-year-old postmenopausal female patient presented to the Xi Jing Hospital of Air Force Medical University in September 2019. She complained of a mass in her left breast for several months.

*History of past illness*

Negative

*Personal and family history*

Her family history of cancer was negative.

*Physical examination*

She found two irregular nodules in the upper external quadrant of the left breast.
Laboratory examinations
All tumor markers, including serum carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), and alpha fetoprotein (AFP), were within normal ranges. Histopathology revealed invasive breast carcinoma and infiltrating ductal carcinoma in the axillary lymph nodes. Immunohistochemical (IHC) staining was positive for estrogen receptor (ER), progesterone receptor (PR), Ki-67 30% and suspicious positive for human epidermal receptor -2 (HER-2). Because of the suspicious positivity for HER-2, the fluorescence in situ hybridization (FISH) method was strongly recommended. FISH testing was positive, as shown in Figure 1. Breast cancer and metastatic lymph nodes were identical in FISH expression. The physical and imaging examinations showed no primary lesions in either breast or in other organs.

Imaging examinations
Ultrasonographic (US) examination showed two irregular nodules in the upper external quadrant of the left breast. The largest mass was 2.6×0.9×1.1 cm in diameter, with invasion of deeper structures. Doppler ultrasound showed a fixed, 2-cm lymph nodule.

FINAL DIAGNOSIS
HER2+ breast cancer

TREATMENT
The multidisciplinary board of the Breast Centre recommended “neoadjuvant” chemotherapy: T(HP)-EC scheme: 4 cycles of docetaxel 90 mg/m², trastuzumab, and pertuzumab, followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m², every 3 wk for 8 cycles) before total mastectomy and axillary lymph node dissection. Histopathologic analysis of these specimens showed residual ductal carcinoma disease. Histopathology revealed grade 3 invasive breast carcinoma, (RCB-II, 6 scores). Microscopically, the residual invasive breast cancer was approximately 7 mm,
and 5 out of 20 dissected axillary lymph nodes showed metastasis. With all of this, the
tumour was classified as ypT1bN2aM0. Immunohistochemistry was performed, and the
results were as follows: 90% positivity for estrogen receptors with high intensity, 90%
positivity for progesterone receptors with high intensity, and suspicious positivity for
HER-2 (++) FISH testing was negative, as shown in Figure 2. We retrospectively
reevaluated these results from the central laboratory FISH screening. On May 8, 2020,
the patient received T-DM1 at a dose of 3.6 mg per kilogram of body weight
intravenously every 3 wk for 14 cycles. Simultaneously, adjuvant radiotherapy was also
recommended because of her axillary lymph node features on excisional biopsy. At the
follow-up, 1 year after diagnosis and treatment initiation, the patient had no sign of
local or distant recurrence. Considering the hormone sensitivity of the tumour, the
guidelines decided for endocrine adjuvant therapy were as follows: (abemaciclib 150
mg twice daily + anastrozole 1mg once daily).

OUTCOME AND FOLLOW-UP

At the time of drafting the present report (January 2022), routine follow-up of the
patient continued, showing no complications.

DISCUSSION

The current standard presurgical systemic treatment in HER2-positive breast
cancer patients is neoadjuvant treatment (NAT), especially for positive pathologic
axillary lymph nodes. The addition of anti-HER2 treatment to neoadjuvant
chemotherapy significantly improves the pathological complete response (pCR) rate,
which is a surrogate for disease-free survival (DFS), overall survival (OS) and distant
recurrence-free survival (DRFS). Mittendorf et al found that according to FISH
analysis, approximately one-third of their patients with sufficient residual disease to
warrant repeat HER2 testing had lost HER2 gene amplification. Furthermore, patients
who lose HER2 gene amplification have significantly lower relapse-free survival than
those whose tumours retain HER2 gene amplification. Notably, we found that this
case exhibited changes in the expression of HER2 receptors on tumour samples from surgical specimens obtained after NAT compared with initial biopsy. This is in agreement with early studies in which the rate of HER2 gain and loss was observed to be 6.5% and 14.2%, respectively, and loss of HER2 expression was more commonly observed than gain of HER2 expression\textsuperscript{[3-7]}. In the neoadjuvant setting, the addition of trastuzumab and, more recently, pertuzumab to chemotherapy significantly improves the pathological complete response (pCR) rate compared to chemotherapy alone\textsuperscript{[8]}. The KATHERINE study showed that among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer or death was 50% lower with adjuvant trastuzumab emtansine (T-DM1) than with trastuzumab alone. Further subgroup analyses showed that 8.3% of posttreatment tumours lost HER2 positivity after NAT (n = 70); invasive-disease events occurred in 11 patients in the adjuvant trastuzumab group; and no events occurred in the T-DM1 group, reminding us that adjuvant T-DM1 remains beneficial in tumour loss in the HER2 population\textsuperscript{[9]}. This case was HR+,HER2+ breast cancer. The ExteNET trial demonstrated that neratinib given for 1 year following trastuzumab-based therapy significantly improved invasive disease-free survival (iDFS) in patients with HER2+ breast cancer, with the greatest efficacy seen in patients who initiated treatment within 1 year of prior trastuzumab therapy and in those with HR+ disease\textsuperscript{[10]}. Meanwhile, the most recently results showed that neratinib achieved an 11.9% iDFS benefit for the HR+ subgroup within 1 year of prior trastuzumab therapy in the 5-year analysis. In comparison with the previously reported KATHERINE trial, the iDFS benefit was 11.3% at the 3-year analysis in patients with T-DM1. However, patients in the KATHERINE trial had a substantially worse baseline prognosis than those enrolled in the ExteNET trial. The KATHERINE trial focused on higher-risk patients with residual invasive breast cancer after completion of neoadjuvant chemotherapy administered with trastuzumab-containing therapy. We considered that the patient could benefit from T-DM1 rather than neratinib, owing to adverse events, group characteristics and
accessibility. Subsequently, the MonarchE study showed that there was a 25% reduction in the risk of developing an iDFS event in the abemaciclib plus endocrine therapy (ET) group relative to ET alone, as well as a 3.5% absolute improvement in 2-year IDFS rates (92.2% v 88.7%). The addition of abemaciclib to ET also resulted in an improvement in DRFS (distant relapse-free survival) compared with ET alone, with 2-year DRFS rates of 93.6% in the abemaciclib arm and 90.3% in the control arm\textsuperscript{[11–13]}. 

In general, the exact mechanisms of HER2 discordance remain unknown and further investigations are needed. The interval between the last HER2-targeted treatment, the time of surgical excision of the tumour after NAT, and biopsy of the metachronous metastasis or intratumoural heterogeneity of the HER2 gene were associated with a significant change in HER2 expression. Nevertheless, FISH testing is associated with less discordance than the IHC method\textsuperscript{[2, 13]}. Despite observations revealing HER2 Loss between initial biopsy and surgical specimens, management of patients with HER2+ breast cancer is frequently based on primary tumor characteristics. Furthermore, several studies suggested that all subgroups of women seem to benefit from trastuzumab in exploratory subgroup analysis, regardless of changes in HER status\textsuperscript{[13–16]}. In our opinion, changes in HER2 expression after NAT should be retested by physicians and pathologists before systemic treatment instead of avoiding further HER2-targeted therapy. Furthermore, if the HER2 status changes between the primary tumour and the remaining tumour undergoing NAT, the actual guidelines recommend the use of HER2 status in metastatic tissue, and the FISH method is strongly recommended. In this way, changes in HER2 expression influenced by HER2 internalization and degradation may be avoided. Finally, we will perform IHC multiple-spot biopsy analyses of other important clinical issues to better define prognosis and tailor subsequent adjuvant therapy.

**CONCLUSION**

In conclusion, our study presented a case of HER+ gene loss in a patient with the HER2+ breast cancer after NAT and we went on to do a literature review of this
phenomenon which has been shown in about 10% of patient in case series. Although HER2 Loss after NAT is considered extremely rare, repeating HER2 test or IHC multiple-spot biopsy analyses is required for accurate prognosis and therapy.
### PRIMARY SOURCES

<table>
<thead>
<tr>
<th>#</th>
<th>Source</th>
<th>Words %</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td><a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a></td>
<td>70 words — 4%</td>
</tr>
<tr>
<td>2</td>
<td>Tanja Ignatov, Franceska Gorbunow, Holm Eggemann, Olaf Ortmann, Atanas Ignatov. &quot;Loss of HER2 after HER2-targeted treatment&quot;, Breast Cancer Research and Treatment, 2019 Crossref</td>
<td>48 words — 3%</td>
</tr>
<tr>
<td>3</td>
<td>static-curis.ku.dk</td>
<td>45 words — 3%</td>
</tr>
<tr>
<td>4</td>
<td>jbuon.com</td>
<td>42 words — 2%</td>
</tr>
<tr>
<td>5</td>
<td>academic.oup.com</td>
<td>41 words — 2%</td>
</tr>
<tr>
<td>6</td>
<td><a href="http://www.nejm.org">www.nejm.org</a></td>
<td>23 words — 1%</td>
</tr>
<tr>
<td>7</td>
<td>eprints.aihta.at</td>
<td>21 words — 1%</td>
</tr>
</tbody>
</table>
| 8  | Kopetti Camille, Schaffer Clara, Zaman Khalil, Liapi Aikaterini, di Summa Pietro Giovanni, Bauquis Olivier. "Invasive Breast Cancer in a Female-to-Male
| Transgender after Bilateral Mastectomy: case-report and Literature Review", Clinical Breast Cancer, 2020
| Crossref

| 9 | www.science.gov
Internet |
| 19 words — 1% |

| 10 | Ruixin Xu, Jianbin Li, Yingjie Zhang, Hongbiao Jing, Youzhe Zhu. "Male occult breast cancer with axillary lymph node metastasis as the first manifestation", Medicine, 2017
| Crossref |
| 17 words — 1% |

| 11 | www.esmo.org
Internet |
| 17 words — 1% |

| 12 | www.wjgnet.com
Internet |
| 17 words — 1% |

**EXCLUDE QUOTES** | ON |
**EXCLUDE BIBLIOGRAPHY** | OFF |
**EXCLUDE MATCHES** | < 15 WORDS |